Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
H. Lundbeck AS, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
H. Lundbeck AS, Medical Devices Deals, 2011 to YTD 2017 11
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
Lundbeck Acquires Desmoteplase, Ischaemic Stroke Drug From Paion For US$27 Million 15
Venture Financing 17
Naurex Raises USD80 Million in Series C Venture Financing 17
Naurex Raises US$25 Million In Venture Financing 19
Naurex Raises US$38 Million In Series B Financing 21
Partnerships 23
Confo Therapeutics Enters into Agreement with H. Lundbeck 23
Cerveau Technologies Enters into Research Agreement with Lundbeck 24
H. Lundbeck Enters into Agreement with 23andMe and Milken Institute 25
Lundbeck Enters into Research Agreement with ImmunoBrain Checkpoint 26
H. Lundbeck Enters into Agreement with IBM Watson Health 27
Circuit Therapeutics Enters into Research Agreement with H. Lundbeck 28
Ossianix Expands and Extends Research Agreement with Lundbeck 29
Nanomerics, University College London and Lundbeck Enter Collaboration Agreement 30
Ossianix Enters Into Co-Development Agreement With Lundbeck 31
Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma For Lu AF20513 32
Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma 33
Upsher-Smith Labs Enters Into Development Agreement With Lundbeck 34
Otsuka Pharma Enters Into Co-Promotion Agreement Lundbeck For Abilify 35
ImaginAb Enters Into Co-Development Agreement With H. Lundbeck For CNS Imaging Biologics 36
Lundbeck Plans To Enters Into Co-Development Agreement For Treatment Of Alzheimer’s Disease 37
Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma 38
Almirall Enters Into Co-Promotion Agreement With Lundbeck For Escitalopram 40
H. Lundbeck Enters Into Co-Development Agreement With Proximagen 41
Lundbeck Enters Into Collaboration With The University Of Massachusetts 42
Licensing Agreements 44
Lundbeck Enters into Licensing Agreement with Ovid Therapeutics for Gaboxadol 44
Lundbeck Enters Into Licensing Agreement With Otsuka Pharma For Lu AE58054 45
Lundbeck Enters Into Licensing Agreement With Cephalon 46
Equity Offering 47
H. Lundbeck Raises USD0.3 Million in Private Placement of Shares upon Exercise of Warrants 47
H. Lundbeck to Raise USD3.2 Million in Private Placement of Shares upon Exercise of Warrants 48
Chelsea Therapeutics Completes Public Offering Of Shares For US$23 Million 49
Chelsea Therapeutics Files Shelf Registration Statement For Public Offering Of US$100 Million 50
Chelsea Therapeutics Completes Public Offering Of Common Stock For US$24 Million 51
Chelsea Therapeutics International Completes Public Offering Of Its Common Stock For US$40.3 Million 53
Asset Transactions 55
Recordati Completes Acquisition Of Portfolio Of Products From Lundbeck For US$100 Million 55
Oak Pharma Acquires Three Hospital-Based Injectables From H. Lundbeck 58
Trygg Pharma Completes Acquisition Of Manufacturing Facility In UK From Lundbeck Pharma 59
Acquisition 60
H. Lundbeck Completes Acquisition of Chelsea Therapeutics for USD658 Million 60
Lundbeck Acquires 4.6% Stake In Biotie Therapies For US$13 Million 62
H. Lundbeck AS – Key Competitors 63
H. Lundbeck AS – Key Employees 64
H. Lundbeck AS – Locations And Subsidiaries 65
Head Office 65
Other Locations & Subsidiaries 65
Recent Developments 69
Financial Announcements 69
Nov 08, 2017: Lundbeck increased operating profit (EBIT) with 126% and EPS by 182% in the first nine months of 2017 69
Aug 09, 2017: Lundbeck reports 13% revenue growth and a doubling of EBIT in first half of 2017 70
May 10, 2017: Lundbeck: 2017 guidance raised based on strong revenue growth and improved profitability 77
Feb 08, 2017: Lundbeck continues to show solid revenue growth and strong improvement in profitability 78
Nov 02, 2016: Lundbeck raises its 2016 financial guidance based on improved sales and profitability 79
Aug 24, 2016: Lundbeck increased revenue by 5% driven by US sales growth of 33% leading to improved profitability and increased financial guidance for 2016 80
May 11, 2016: 2016 guidance raised based on solid sales performance and improved profitability 82
Feb 10, 2016: Solid sales performance in 2015 and return to profitability in 2016 83
Corporate Communications 84
Oct 30, 2017: Changes to Lundbeck’s Executive Management 84
Sep 11, 2017: Changes in Executive Management in Lundbeck 85
Legal and Regulatory 86
Sep 08, 2016: The General Court of the EU upholds the European Commission’s 2013 fining decision against Lundbeck 86
Product News 87
Dec 02, 2017: Study Evaluates Refractory Epilepsy Screening Tool for LGS (REST-LGS) 87
Aug 02, 2017: 23andMe Enrolling For First-of-its-Kind Study on Major Depressive and Bipolar Disorders 88
Apr 18, 2017: Lundbeck to Present Data on Movement Disorder and Epilepsy Therapies at AAN Annual Meeting 89
Mar 03, 2017: Bioneer: In the Forefront of Developing New Human Cell Models for Neurodegenerative Diseases 90
Product Approvals 91
Apr 22, 2016: FDA Accepts Lundbeck Resubmission of New Drug Application for Carnexiv (carbamazepine) 91
Clinical Trials 92
Mar 11, 2016: Lundbeck starts clinical phase III program with Lu AF35700 in patients with treatment resistant schizophrenia 92
Appendix 93
Methodology 93
About GlobalData 93
Contact Us 93
Disclaimer 93
H. Lundbeck AS, Pharmaceuticals & Healthcare, Key Facts, 2016 2
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
H. Lundbeck AS, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
H. Lundbeck AS, Deals By Therapy Area, 2011 to YTD 2017 10
H. Lundbeck AS, Medical Devices Deals, 2011 to YTD 2017 11
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Lundbeck Acquires Desmoteplase, Ischaemic Stroke Drug From Paion For US$27 Million 15
Naurex Raises USD80 Million in Series C Venture Financing 17
Naurex Raises US$25 Million In Venture Financing 19
Naurex Raises US$38 Million In Series B Financing 21
Confo Therapeutics Enters into Agreement with H. Lundbeck 23
Cerveau Technologies Enters into Research Agreement with Lundbeck 24
H. Lundbeck Enters into Agreement with 23andMe and Milken Institute 25
Lundbeck Enters into Research Agreement with ImmunoBrain Checkpoint 26
H. Lundbeck Enters into Agreement with IBM Watson Health 27
Circuit Therapeutics Enters into Research Agreement with H. Lundbeck 28
Ossianix Expands and Extends Research Agreement with Lundbeck 29
Nanomerics, University College London and Lundbeck Enter Collaboration Agreement 30
Ossianix Enters Into Co-Development Agreement With Lundbeck 31
Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma For Lu AF20513 32
Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma 33
Upsher-Smith Labs Enters Into Development Agreement With Lundbeck 34
Otsuka Pharma Enters Into Co-Promotion Agreement Lundbeck For Abilify 35
ImaginAb Enters Into Co-Development Agreement With H. Lundbeck For CNS Imaging Biologics 36
Lundbeck Plans To Enters Into Co-Development Agreement For Treatment Of Alzheimer’s Disease 37
Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma 38
Almirall Enters Into Co-Promotion Agreement With Lundbeck For Escitalopram 40
H. Lundbeck Enters Into Co-Development Agreement With Proximagen 41
Lundbeck Enters Into Collaboration With The University Of Massachusetts 42
Lundbeck Enters into Licensing Agreement with Ovid Therapeutics for Gaboxadol 44
Lundbeck Enters Into Licensing Agreement With Otsuka Pharma For Lu AE58054 45
Lundbeck Enters Into Licensing Agreement With Cephalon 46
H. Lundbeck Raises USD0.3 Million in Private Placement of Shares upon Exercise of Warrants 47
H. Lundbeck to Raise USD3.2 Million in Private Placement of Shares upon Exercise of Warrants 48
Chelsea Therapeutics Completes Public Offering Of Shares For US$23 Million 49
Chelsea Therapeutics Files Shelf Registration Statement For Public Offering Of US$100 Million 50
Chelsea Therapeutics Completes Public Offering Of Common Stock For US$24 Million 51
Chelsea Therapeutics International Completes Public Offering Of Its Common Stock For US$40.3 Million 53
Recordati Completes Acquisition Of Portfolio Of Products From Lundbeck For US$100 Million 55
Oak Pharma Acquires Three Hospital-Based Injectables From H. Lundbeck 58
Trygg Pharma Completes Acquisition Of Manufacturing Facility In UK From Lundbeck Pharma 59
H. Lundbeck Completes Acquisition of Chelsea Therapeutics for USD658 Million 60
Lundbeck Acquires 4.6% Stake In Biotie Therapies For US$13 Million 62
H. Lundbeck AS, Key Competitors 63
H. Lundbeck AS, Key Employees 64
H. Lundbeck AS, Subsidiaries 65
